» Articles » PMID: 21051560

The MiR-200 Family Controls Beta-tubulin III Expression and is Associated with Paclitaxel-based Treatment Response and Progression-free Survival in Ovarian Cancer Patients

Abstract

Ovarian cancer remains one of the leading causes of cancer deaths. Thus, new biomarkers predictive of response to the standard paclitaxel-carboplatin treatment are needed to improve chemotherapy strategies. MicroRNAs have the potential to modify drug outcomes. Based on this, we have demonstrated in this study that patients with a high expression of the miR-200 family show low levels of β-tubulin class III in ovarian carcinoma. In addition, we have established the clinical relevance of these microRNAs for ovarian cancer patients' treatment response and survival. In a well-characterized series of 72 ovarian carcinomas, the expressions of miR-141, miR-200a, miR-200b, miR-200c, and miR-429 were quantified by quantitative reverse transcription-PCR, and the protein content of β-tubulin isotypes I, II, and III was determined by immunohistochemistry. The relationship between these microRNAs, β-tubulin expression, response to paclitaxel-based treatment, progression-free survival (PFS) and overall survival was determined. While isotype I had constant high levels, protein expression of β-tubulins II and III was mutually exclusive. Low tumoral miR-200 expression was significantly associated with high β-tubulin III protein content (P values range, 0.047-<0.0001), and patients without complete response (CR) had lower miR-200c levels than patients with CR (hazard ratio (HR)=1.43, 95% confidence interval (CI)=1.02-1.99, P=0.037, multivariate analysis). Additionally, low miR-200 family expression had a trend toward poor PFS (HR>2.0, P values 0.051, 0.054, and 0.079 for miR-200c, miR-141, and miR-429 respectively, multivariate analysis). In conclusion, miR-200 family members affect the final β-tubulin III protein content of ovarian carcinomas. Furthermore, these microRNAs might constitute the biomarkers of response to paclitaxel-based treatments and relapse/progression of advanced stage ovarian carcinoma patients.

Citing Articles

MiRNA Dysregulation in Brain Injury: An Study to Clarify the Role of a MiRNA Set.

Sessa F, Pomara C, Schembari F, Esposito M, Capasso E, Pesaresi M Curr Neuropharmacol. 2024; 23(2):209-231.

PMID: 39129166 PMC: 11793054. DOI: 10.2174/1570159X22666240808124427.


Overexpression of miR-200s inhibits proliferation and invasion while increasing apoptosis in murine ovarian cancer cells.

Carter R, Petrik J, Moorehead R PLoS One. 2024; 19(7):e0307178.

PMID: 39028700 PMC: 11259287. DOI: 10.1371/journal.pone.0307178.


An overview of challenges associated with exosomal miRNA isolation toward liquid biopsy-based ovarian cancer detection.

Bhadra M, Sachan M Heliyon. 2024; 10(9):e30328.

PMID: 38707279 PMC: 11068823. DOI: 10.1016/j.heliyon.2024.e30328.


Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool.

Bhadra M, Sachan M, Nara S Front Mol Biosci. 2024; 11:1361601.

PMID: 38690293 PMC: 11058280. DOI: 10.3389/fmolb.2024.1361601.


MiRNAs related in signaling pathways of women's reproductive diseases: an overview.

Bagheri M, Khansarinejad B, Mondanizadeh M, Azimi M, Alavi S Mol Biol Rep. 2024; 51(1):414.

PMID: 38472662 DOI: 10.1007/s11033-024-09357-0.